Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Importance: The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown. Objective: To evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with placebo for the treatment of early mild to moderate COVID-19. Design, Setting, and Participants: ACTIV-6, an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial, was designed to evaluate repurposed therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30 years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022, with follow-up data through May 31, 2022, at 91 sites in the US. Interventions: Participants were randomized to receive ivermectin, 400 μg/kg (n = 817), daily for 3 days or placebo (n = 774). Main Outcomes and Measures: Time to sustained recovery, defined as at least 3 consecutive days without symptoms. There were 7 secondary outcomes, including a composite of hospitalization or death by day 28. Results: Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932 women [58.6%]; 753 [47.3%] reported receiving at least 2 doses of a SARS-CoV-2 vaccine), 1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07 (95% credible interval [CrI], 0.96-1.17; posterior P value [HR >1] = .91). The median time to recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the placebo group (1.2% vs 1.2%; HR, 1.1 [95% CrI, 0.4-2.6]). The most common serious adverse events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous thromboembolism (ivermectin [n = 1]; placebo [n = 5]). Conclusions and Relevance: Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. Trial Registration: ClinicalTrials.gov Identifier: NCT04885530
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kory, P., Meduri, G. U., Iglesias, J., Varon, J., & Marik, P. E. (2021) · Journal of Intensive Care Medicine · doi:10.1177/0885066620973585 · Cited by 32
RetractedDexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Lenze, E. J., Mattar, C., Zorumski, C. F., Stevens, A., Schweiger, J., Nicol, G. E., Miller, J. P., Yang, L., Yingling, M., Avidan, M. S., et al. (2020) · JAMA · doi:10.1001/jama.2020.22760 · Cited by 495
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Hill, A., Mirchandani, M., & Pilkington, V. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab645 · Cited by 57
Cited by
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.1650 · Cited by 79
Self-citationHayward, G., Yu, L.-M., Little, P., Gbinigie, O., Shanyinde, M., Harris, V., Dorward, J., Saville, B. R., Berry, N., Evans, P. H., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106130 · Cited by 31
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Wali, A. F., Rangraze, I. R., Babiker, R., Rabbani, S. A., El-Tanani, Y., & Rizzo, M. (2025) · Antibiotics · doi:10.3390/antibiotics14050459 · Cited by 9
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia del Sol, I. T., et al. (2025) · doi:10.1101/2025.01.13.25320485 · Cited by 8
Self-citationBramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia del Sol, I. T., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.2570 · Cited by 8
Self-citation
Metadata
- Authors
- Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N., Collins, S., McCarthy, M. W., Jayaweera, D., Castro, M., Sulkowski, M., McTigue, K., Thicklin, F., Felker, G. M., Ginde, A. A., Bramante, C. T., Slandzicki, A. J., Gabriel, A., Shah, N. S., Lenert, L. A., Dunsmore, S. E., Adam, S. J., DeLong, A., Hanna, G., Remaly, A., Wilder, R., Wilson, S., Shenkman, E., Hernandez, A. F., Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators, Vincent, W. (., Vincent, R., Bianchi, R., Premas, J., Cordero-Loperena, D., Rivera, E., Gupta, M., Karawan, G., Ziomek, C., Arena, J., DeAlmeida, S., Ramin, S., Nataraj, J., Paasche-Orlow, M., Henault, L., Waite, K., Miller, D., Brounce, G., George-Adebayo, C., Adebayo, A., Wallan, J., Slandzicki, A., Vogel, C., Munoz, S., Kavtaradze, D., Watson, C., Singleton, D., Rivon, M., Sevier, A., Del Pilar, A., Spangler, A., Rao, S., Cantu, L., Krishna, A., Evans, K., Falkner, T., Kerr, B., Spees, R., Marta, M., Felker, G. M., Harrington, A., Dolor, R., Frazier, M., Vergara, L., Wilson, J., Burruss, V., Hurst, T., Ofotokun, I., Bristow, L., Prabhu, R., Klicka, K., Lightfeather, A., James, V., Rogers, M., Parihar, P., Torress, D., Oragwu, C., Oguego, N., Pillai, R., Juma, M., Gabriel, A., Ghaly, E., Al-Haddadin, D., Ramirez, C., Hassanien, G., Ismail, S., Meltzer, A., Moran, S., Brehaut, S., Roche, A., Mehta, M., Koppinger, N., Baez, J., Pagan, I., Abdelsayed, D., Aziz, M., Robinson, P., Nguyen, J., Pardue, V., Hammons, L., Ruiz-Unger, J., Gonzalez, S., Reyes, L., Cienki, J., Jimenez, G., Cohen, J., Wong, M., Yuan, Y., Szeto, J., Sulkowski, M., Stelmash, L., Amon, A., Haight, D., Lamb, D., Harper, A., Pyram-Bernard, N., Quintero, A., Adhami, E., Maria, J., Paudel, D., Raymond, O., Summers, J., Turner, T., Lenert, L., Gallegos, S., Szwast, E. A., Abdulghani, A., Vasoya, P., Miller, C., Wiley, H., Shah, N., Klein, T., Castex, J., Feliciano, P., Olivo, J., Ghaly, M., Javed, Z., Nawrocki, A., Vecchiarelli, A., Vigil, N., Cherukuri, V., Burden, E., Linn, D., Fisher, L., Patel, V., Patel, P., Patel, Y., Ellison, L., Harrison, J., Shah, B., Shah, S., Singh, U., Donahue, J., Jazayeri, Y., Gupta, A., Chandrasekar, N., Moritz, B., Fortt, T., Fortt, A., Jones-Ince, I., McKee, A., Schattinger, C., Wilson, J., Farlow, B., Gentile, N., Finlaw, L., Richwine, R., Williams, T., Paizer, P., Carson, L., Michelson, E., Austin, D., Khetpal, S., Cantrell, T., Franklin, D., Marshall, K., Mahadevan, A., Rosequist, M., Gnoni, M., Daffner, C., VandeWeerd, C., Roberts, M., D'Andrea, M., Lim, S., Swink, W., Powers-Fletcher, M., Mukunzi, S., Shenkman, E., Hensley, J., Manning, B., Isache, C., Bowman, J., Callaghan-Brown, A., Scott, T., Schwasinger-Schmidt, T., Cornejo, A., Jayaweera, D., Almanzar, M., Ginsburg, L., Hajaz, A., Bramante, C., Robinson, M., Seithel, M., Sekikawa, A., Klawson, E., Ostrosky, L., Umana, V., Patterson, T., Tragus, R., Jackson, P., Hallowell, C., Haughey, H., Vaidya-Tank, B., Gould, C., Goyal, P., Gatewood, C., Williamson, J., Seagle, H., McCarthy, M., Salsgiver, E., Armas, E., Cheng, J., Huerta, P., Garcia-Diaz, J., Aamodt, D., Ayers, J., Collins, J., Graves, J., Grindstaff, J., Harrell, F., Lai, J., Lopez, I., Marlin, J., Merkel, A., Nwosu, S., Obregon, S., Orozco, D., Perez-Torres, Y., Prato, N., Ratcliff, C., Rhode, M., Rothman, R., Shirey-Rice, J., Vermillion, K., Tan, H.-N., Tregoning, S., Vance, M., Vongsamphanh, A., Weir, M., & Zaleski, N.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-10-25
- Volume
- 328
- Issue
- 16
- Pages
- 1595
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4307043809
- Cited by
- 95
- References
- 7
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2022.18590
- The paper
- Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N., Collins, S., McCarthy, M. W., Jayaweera, D., Castro, M., Sulkowski, M., McTigue, K., Thicklin, F., Felker, G. M., Ginde, A. A., Bramante, C. T., Slandzicki, A. J., Gabriel, A., Shah, N. S., Lenert, L. A., . . . Zaleski, N. (2022). Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2022.18590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.